The diagnostic value of enzyme immunoassay and immunoblot in monitoring eradication of Helicobacter pylori

被引:62
作者
Sorberg, M
Engstrand, L
Strom, M
Jonsson, KA
Jorbeck, H
Granstrom, M
机构
[1] LINKOPING UNIV HOSP,DEPT CLIN MICROBIOL,S-58185 LINKOPING,SWEDEN
[2] UNIV UPPSALA HOSP,DEPT CLIN MICROBIOL & CANCEREPIDEMIOL,UPPSALA,SWEDEN
[3] LINKOPING UNIV HOSP,DEPT MEDICOSURG GASTROENTEROL,S-58185 LINKOPING,SWEDEN
[4] DANDERYD HOSP,DEPT CLIN MICROBIOL,S-18288 DANDERYD,SWEDEN
[5] KAROLINSKA HOSP,DEPT CLIN MICROBIOL,S-10401 STOCKHOLM,SWEDEN
关键词
D O I
10.3109/00365549709035875
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
55 patients with severe ulcer disease and H. pylori infection, successfully treated with antimicrobials, were followed-up with repeated blood samples for up to 32 months. Sera were analysed by enzyme immunoassay (ETA) for IgG and IgA antibodies and by IgG immunoblot. The EIA for IgG antibodies showed a high sensitivity (100%), while IgA antibodies above the cut-off level were found in 55% of the patients. At a median of 77 days after onset of treatment, approximately 50% of the patients showed a significant decrease (greater than or equal to 50%) of IgG or had titres below the cut-off level. All patients but 1 had a significant decrease of IgG after 6-12 months. The decrease was slower for IDA. The Ii. pylori-specific 116 kDa and 19.5 kDa bands were found in all pre-treatment samples, but the decrease in median intensity of the bands was slower than for the Ige EIA. In the 32-months post-treatment samples, both bands had an intensity still above 50% of the pre-treatment value. The study showed that the Ige EIA is a useful method for monitoring eradication of H. pylori. Immunoblot can detect previous H. pylori infection in EIA negative individuals.
引用
收藏
页码:147 / 151
页数:5
相关论文
共 19 条
[1]   HELICOBACTER-PYLORI IN 205 CONSECUTIVE ENDOSCOPY PATIENTS [J].
BEFRITS, R ;
GRANSTROM, M ;
RYLANDER, M ;
RUBIO, C .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1993, 25 (02) :185-191
[2]   SYSTEMIC AND MUCOSAL HUMORAL RESPONSES TO HELICOBACTER-PYLORI IN GASTRIC-CANCER [J].
CRABTREE, JE ;
WYATT, JI ;
SOBALA, GM ;
MILLER, G ;
TOMPKINS, DS ;
PRIMROSE, JN ;
MORGAN, AG .
GUT, 1993, 34 (10) :1339-1343
[3]   ROLE OF HELICOBACTER-PYLORI SEROLOGY IN EVALUATING TREATMENT SUCCESS [J].
CUTLER, A ;
SCHUBERT, A ;
SCHUBERT, T .
DIGESTIVE DISEASES AND SCIENCES, 1993, 38 (12) :2262-2266
[4]  
Cutler AF, 1996, AM J GASTROENTEROL, V91, P85
[5]  
DIXON MF, 1992, EUR J GASTROENTER S2, V4, P17
[6]   ALTERNATIVE MANAGEMENT STRATEGIES FOR PATIENTS WITH SUSPECTED PEPTIC-ULCER DISEASE [J].
FENDRICK, AM ;
CHERNEW, ME ;
HIRTH, RA ;
BLOOM, BS .
ANNALS OF INTERNAL MEDICINE, 1995, 123 (04) :260-268
[7]   HELICOBACTER-PYLORI INFECTION - INDEPENDENT RISK INDICATOR OF GASTRIC ADENOCARCINOMA [J].
HANSSON, LE ;
ENGSTRAND, L ;
NYREN, O ;
EVANS, DJ ;
LINDGREN, A ;
BERGSTROM, R ;
ANDERSSON, B ;
ATHLIN, L ;
BENDTSEN, O ;
TRACZ, P .
GASTROENTEROLOGY, 1993, 105 (04) :1098-1103
[8]   PREVALENCE OF HELICOBACTER-PYLORI INFECTION IN SUBTYPES OF GASTRIC-CANCER [J].
HANSSON, LE ;
ENGSTRAND, L ;
NYREN, O ;
LINDGREN, A .
GASTROENTEROLOGY, 1995, 109 (03) :885-888
[9]   EFFECT OF RANITIDINE AND AMOXICILLIN PLUS METRONIDAZOLE ON THE ERADICATION OF HELICOBACTER-PYLORI AND THE RECURRENCE OF DUODENAL-ULCER [J].
HENTSCHEL, E ;
BRANDSTATTER, G ;
DRAGOSICS, B ;
HIRSCHL, AM ;
NEMEC, H ;
SCHUTZE, K ;
TAUFER, M ;
WURZER, H .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (05) :308-312
[10]   KINETICS OF SPECIFIC IGG ANTIBODIES FOR MONITORING THE EFFECT OF ANTI-HELICOBACTER-PYLORI CHEMOTHERAPY [J].
HIRSCHL, AM ;
BRANDSTATTER, G ;
DRAGOSICS, B ;
HENTSCHEL, E ;
KUNDI, M ;
ROTTER, ML ;
SCHUTZE, K ;
TAUFER, M .
JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (03) :763-766